display
Bad Homburg (dpa) - The health group Fresenius makes the former Siemens manager Michael Sen the new head of its drug subsidiary Kabi.
The 52-year-old will follow Mats Henriksson there on April 12, as the Dax group announced in Bad Homburg on Tuesday.
The 53-year-old is leaving Kabi because of different ideas about the future direction of the Fresenius subsidiary.
Sen brings experience with the spin-off of parts of the company from his previous jobs at Siemens and Eon: As Eon's CFO, the manager organized the outsourcing of the electricity and gas business to Uniper.
At Siemens, he was responsible for the health business and later for the energy sector, which the company listed on the stock exchange under the names Siemens Healthineers and Siemens Energy.
When moving chairs on the Siemens management floor a year ago, Sen surprisingly did not rise to the top of Siemens Energy, but left the company.
The trigger should have been differences about independence and the future business model.
display
The Fresenius liquid medicine subsidiary Kabi offers infusions, anesthetics and clinical nutrition.
Sens appointment as the new boss gives the discussion about the restructuring of the group additional weight, wrote analyst David Adlington of the US bank JPMorgan.
Although Kabi is apparently still allowed to belong to the group, there may be room for the sale of parts of the business.
In the announcement, Fresenius boss Stephan Sturm emphasized that Kabi would remain “of central strategic importance” for the healthcare company.
© dpa-infocom, dpa: 210317-99-855930 / 2
Communication from Fresenius